News | November 01, 2024
AbbVie to acquire Aliada Therapeutics
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Subscribe To Our Newsletter & Stay Updated
